Skip to main navigation Skip to search Skip to main content

24-LEUK-26-OV (OV-AML-1231): A Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Grants and Contracts Details

StatusActive
Effective start/end date9/4/24 → 9/4/27

Funding

  • OncoVerity Incorporated: $84,678.00